The Hello Bar is a simple web toolbar that engages users and communicates a call to action.

February 4, 2012

Phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis

AstraZeneca

AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. Sepsis occurs when the body’s immune system sets off a chain reaction and “overreacts” to an infection. [...]

What is the minimum APACHE II scored needed in order to initiate Xigris (Drotrecogin Alfa) therapy in an adult patient with severe sepsis?

What is the minimum APACHE II scored needed in order to initiate Xigris (Drotrecogin Alfa) therapy in an adult patient with severe sepsis? Send your answer to rxquiz@rxtimes.com for a chance to be selected to receive a free RxTimes Magazine travel coffee mug! Only confirmed subscribers are eligible. Please subscribe to RxTimes Magazine before submitting your [...]

© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.